| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(3 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(3 years from now) | |
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(3 years from now) | |
| US11547758 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(3 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(4 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(4 years from now) | |
Cardene is owned by Chiesi.
Cardene contains Nicardipine Hydrochloride.
Cardene has a total of 6 drug patents out of which 0 drug patents have expired.
Cardene was authorised for market use on 30 January, 1992.
Cardene is available in injectable;intravenous, injectable;injection dosage forms.
Cardene can be used as method for treating acute elevations of blood pressure in human subject in need thereof.
The generics of Cardene are possible to be released after 26 December, 2027.
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS
CARDENE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic